Quest Acquires MyPRS Test

We represented Quest Diagnostics (NYSE: DGX) in its acquisition of intellectual property assets relating to MyPRS test from Signal Genetics (NASDAQ: SGNL). Myeloma Prognostic Risk Signature, or MyPRS, test analyzes the activity of genes to predict whether an individual is at high risk or low risk for early relapse. Knowing the risk of relapse helps to predict patient outcome.

Quest Diagnostics is the world’s leading provider of diagnostic information services that patients and doctors need to make better healthcare decisions.

You Also May Be Interested In:

  • We advise a multinational specialty manufacturing and technology company in all domestic and international privacy and data protection matters, including assistance in implementing a privacy compliance program and drafting license and services agreements, including data use and rights terms, and data access and deletion request response procedures.

    We advise a multinational specialty manufacturing and technology company in all domestic and international privacy and data protection matters, including...
    Client Type: Private Company
  • We advise a leading U.S. provider of senior care and assisted living communities with respect to state privacy law, PCI...
    Client Type: Public Company
  • We serve as lead outside counsel for a global Fortune 500 media company negotiating data protection and privacy agreements and contractual terms, including for engagements of ad tech, security infrastructure, financial services, and clinical healthcare service providers, as well as advising on U.S. and international security and privacy regulations and self-regulatory framework compliance.

    We serve as lead outside counsel for a global Fortune 500 media company negotiating data protection and privacy agreements and...
    Client Type: Public Company